Lexicon Pharmaceuticals | LXRX - Себестоимость





Себестоимость Изменить Дата
Abbott USD 5.3B 380M 2026-03
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
Illumina USD 370M 30M 2026-03
Insmed USD 49.5M 3.34M 2026-03
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
J&J USD 8.07B 103M 2026-03
Lexicon Pharmaceuticals USD 201K 191K 2025-12
MacroGenics USD 9.53M 585K 2026-03
MannKind USD 39.58M 5.94M 2026-03
Merck USD 2.94B 380M 2026-03
Moderna USD 955M 503M 2026-03
Novartis USD 3.46B 83M 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Thermo Fisher Scientific USD 6.96B 620M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
United Therapeutics USD 133.4M 341.3M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12